Susan Johnson, CEO and creator of Medfield Pharmaceuticals, is encountered with conflicting recommendations for extending the patent life of the company's main product, Fleximat, scheduled to go off patent in a couple of years. But a current $750 million offer to buy the company has completely shifted her focus.
Medfield Pharmaceuticals Case Study Solution
With this offer, Johnson has the chance to exit the company on a high note. Johnson has to determine the value of the business, with a careful review of its own existing and prospective future products, before making her recommendation. But this is simply a fiscal choice, since Johnson-and Medfield employees in general-consider that the business is engaged in critically important work. This case is intended for executive education, MBA, undergraduate, and MBA exec audiences.
PUBLICATION DATE: November 14, 2011 PRODUCT #: UV5632-PDF-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
HP Labs in Singapore
eBay Inc. (A)
TENET HEALTHCARE (THC)
Anderson Streets
Argentina and the Vulture Funds
Hilti (A): Gearing The Supply Chain For The Future
LeShop: A Success Story In The Online Grocery Market
Ocado: A Successful Online Grocery Business Model?
Plumrose Latinoamericana: Relaunching Deviled Ham In Venezuela (A)
Schindler Service (B)
